In this review:
This review summarises evidence for the use of the fixed-dose combination bronchodilator tiotropium bromide monohydrate/olodaterol hydrochloride (Spiolto® Respimat®), hereafter referred to as tiotropium/olodaterol, in the treatment of chronic obstructive pulmonary disease (COPD). Also discussed is evidence favouring earlier treatment of COPD and the role of bronchodilators in this clinical setting.
Download PDF